A non-canonical strategy may improve cancer radiotherapy

August 28, 2018

Although the success or failure of radiation therapy for cancer has long been associated with the intrinsic radio-resistance or radio-sensitivity of tumor cells, a new approach is demonstrating that radiation can take credit for an additional benefit -- causing highly effective secondary immune responses that can enhance anti-tumor immunity.

In the past decade, researchers Ralph Weichselbaum and Yang Xin Fu have promoted the concept that how the host immune system interacts with therapeutic radiation is just as important as radiation itself. The cellular carnage caused by radiation attracts scavengers, such as dendritic cells. These warriors chew up radiation-damaged cancer cells and present the fragments to T cells that dismantle them.

In the September 18, 2018 issue of the journal Immunity -- available online August 28 -- the Weichselbaum-Fu collaboration demonstrates how specific interactions between therapeutic radiation and a potential patient's innate and adaptive immune responses can improve cancer treatment.

The researchers focused on how two versions of the nuclear factor-κB (NF-κB) signaling pathway respond to radiation therapy in opposing ways. NF-κB1, first described in 1986 by Nobel laureate David Baltimore, was proposed as a major regulator of the immune system's B cells. This canonical pathway -- and the less known 'non-canonical' pathway -- have become a major focus for a variety of areas in biology, including inflammation, immunity and cancer.

"Inhibiting what is known as the canonical NF-κB family has been shown to increase cancer cell killing in tissue culture and has become an area of investigation to improve cancer radiotherapy," said Weichselbaum, MD, professor and chairman of radiation oncology at the University of Chicago. "But despite extensive investigation," he added, "earlier results from these studies failed to improve the response to radiotherapy in animals or humans."

In the current study, teams led by Weichselbaum and Fu, MD, PhD, professor of pathology at the University of Texas Southwestern Medical Center, worked with mice to show that disrupting this pathway actually makes radiotherapy less effective. It inhibits rather than enhances the immune system.

Instead, they found that interfering with the non-canonical NF-κB pathway improved the effects of radiotherapy by enhancing the immune system's ability to interact with radiation. Their findings, obtained in genetic models in mice, were buttressed by biochemical studies. The results suggest novel ways to improve treatment by combining radiation and immunotherapy.

"When we irradiate tumor cells, the immune system essentially gobbles up the DNA they release," Weichselbaum said. The damaged DNA attracts a series of enzymes. These activate a pathway called STING, that recognizes viral and bacterial DNA. "We were surprised to find that it also responded to damaged exogenous DNA," said Weichselbaum.

When they blocked NF-κB, the tumors in the mice got worse instead of better. The immune system in those mice was impaired. When the researchers blocked the non-canonical NF-κB pathway, however, the animals' tumors were more easily eradicated with radiation.

"A lot of drug discovery has been focused on blocking the canonical NF-κB pathway, Weichselbaum said, "but now we think that this impairs the host immune system, whereas blocking the non-canonical NF-κB pathway can improve the host's immune system."

"We have learned that radiation therapy does depend on DNA damage and repair," Fu added. "The host immune system seems to have a lot to do with whether or not radiation works. So by blocking that alternative pathway, rather than the pathway everyone's been focusing on, we think we can get better radio-sensitizing agents, and better results."

This whole interaction between radiation and the immune system is "counterintuitive," Weichselbaum added. "The notion that radiation supplements the immune system is still somewhat controversial," he said.

The damaged DNA "is seen by the immune system as almost like a virus," he said. "The immune system responds as if it were a viral infection, which boosts the overall response. We think this could lead to a whole new therapeutic strategy. Our mice are often cured."

The authors caution that their work, still in animal models, is preliminary.

"We're looking for ways to develop it for people," Weichselbaum said. "It works even better when we add checkpoint inhibitors. This could become a novel combination approach to improving cancer treatment."
-end-
The study was supported by Mr. and Mrs. Vincent Foglia, The Chicago Tumor Institute, the Ludwig Cancer Research Foundation, and NIH grants to Weichselbaum and Fu. Additional authors include Yuzhu Hou, Hua Liang, Enyu Rao, Wenxin Zheng, Xiaona Huang, Liufu Deng, Yuan Zhang, Meng Xu, Helena Mauceri and Ainhoa Arina from the University of Chicago; and Xinshuang Yu, from Shandong University, China.

University of Chicago Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.